OUR SCIENCE & INNOVATION
OUR HYPOTHESIS FOR CANCER THERAPY
The monoclonal antibodies against receptors exposed on the luminal surface of blood vessels associated with diseased organs and tissues, but absent at the level of blood vessels in healthy tissues, offer an opportunity for biomarker-specific delivery of imaging and therapeutic agents.
Our studies have indicated that this is the case for the follicle-stimulating hormone receptor (FSHR).
The generation of highly specific antibodies directed against the FSHR-extracellular domain has allowed us to demonstrate for the first time the selective expression of FSHR in various pathophysiological conditions including cancer, benign tumors, cardiovascular diseases, endometriosis and some rare diseases.
Related Publications
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Vu Hai MT, Ghinea N. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N. Engl. J. Med. 2010, 363, 1621–1630.
Siraj A, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, Ghinea N. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer 2013, 13, 246.
Siraj MA, Pichon C, Radu, Ghinea N. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J. Cell. Mol. Med. 2012, 16, 2010–2016.
Renner M, Goeppert B, Siraj MA, Radu A, Penzel R, Wardelmann E, Lehner B, Ulrich A, Stenzinger A, Warth A, Weichert W, Schirmacher P, Mechtersheimer G, Ghinea N. Follicle-stimulating hormone receptor expression in soft tissue sarcomas. Histopathology 2013, 63, 29–35.
[Google Scholar] [CrossRef] [PubMed]
Planeix F, Siraj MA, Bidard FC, Robin B, Pichon C, Sastre-Garau X, Antoine M, Ghinea N. Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery. J. Exp. Clin. Cancer Res. 2015, 34, 12. [Google Scholar] [CrossRef] [PubMed]
Robin B, Planeix F, Sastre-Garau X, Pichon C, Kold Olesen T, Gogusev J, Ghinea N. Follicle-stimulating hormone receptor expression in the endometriotic lesions and the associated vasculature: An immunohistochemical study. Reproductive Sciences 2016;23(7):885-891.
Ghinea N. Vascular endothelial follicle stimulating hormone receptor, a target of interest for cancer therapy. Endocrinology 2018, 159, 3268–3274.
[Google Scholar] [CrossRef] [PubMed]
Ghinea N. Antibodies against the human FSHR extracellular domain. Available online: https//www.WO2018/172078 A1.
Ghinea N, Robin B, Pichon C et al. Vasa nervorum angiogenesis in prostate cancer with perineural invasion. The Prostate 2019;79:640-46.
Ghinea N. Anti-angiogenic therapy: Albumin-binding proteins could mediate mechanisms underlying the accumulation of small molecule receptor tyrosine kinase inhibitors in normal tissues with potential harmful effects on health. Diseases 2021;9,28
Patents
Ghinea N, Radu A. Use of FSH receptor ligands for diagnosis and therapy of cancer. WO2009/103741.
Ghinea N, Radu A. Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor. Publication number: 20130131136.
Ghinea N. Antibodies against the human FSHR extracellular domain. WO2018172078A.